News

Curetis Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency Initiates set-up of R&D and service laboratory in Vienna Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The Netherlands; January 08, 2019; published at 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level…

Read More

Curetis Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

> Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform > Collaboration leverages Ares Genetics’ antibiotic resistance database ARESdb > Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens Vienna, Austria, Holzgerlingen, Germany and Amsterdam, The Netherlands; December 18, 2018; published at 08:00 am CET – Curetis N.V. (the…

Read More

Curetis Extends Distribution Agreement With Beijing Clear Biotech in China

NEW YORK (GenomeWeb) – Curetis announced today that it has extended an exclusive distribution agreement with Beijing Clear Biotech (BCB), expanding it from five years to eight years following the first Chinese regulatory approval. The strategic collaboration covers distribution of the Curetis Unyvero A50 platform and assay cartridges in China. The amendment to the original…

Read More

Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test

ARESupa test aims at broad detection of microbial infections employing next-generation sequencing and artificial intelligence Curetis explores venture capital (VC) funding for Ares Genetics while assessing all strategic and tactical financing options for growth of Unyvero core business Amsterdam, the Netherlands, Holzgerlingen, Germany, and Vienna, Austria, September 04, 2018, 01:00 am EST – Curetis N.V.…

Read More

Epigenomics Posts 88 Percent Increase in Q2 Revenues

Aug 08, 2018  NEW YORK (GenomeWeb) — Epigenomics reported today an 88 percent year-over-year increase in second quarter revenues amid strong growth in product sales and higher licensing income. For the three-month period ended June 30, Epigenomics’ revenues rose to €462,000 ($535,912) from €246,000 in the same period last year. Product sales — which include…

Read More

Epigenomics AG: Liquid Biopsy Test for Liver Cancer Detection to Obtain CE Mark

– Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2019 – Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 – Epigenomics AG (FSE: ECX,…

Read More

Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge

UTI panel covers 103 diagnostic targets 443-patient multi-center study demonstrates overall weighted average sensitivity of 95.6% at an overall weighted average specificity of 99.3%.  Amsterdam, the Netherlands; San Diego, CA, USA; and Holzgerlingen, Germany; April 19, 2018, 01:00 EDT — Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level…

Read More

Curetis Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority

– Second market authorization for Unyvero Cartridges this year in Singapore Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 04, 2018; published at 11:30 am CEST — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Acumen Research Laboratories Pte. Ltd. (Acumen), its partner for…

Read More

Curetis Subsidiary Ares Genetics Wins Incubator Stay in Silicon Valley

– Award winner in “GoSiliconValley” competition by Austrian Economic Chambers – Support for business development in U.S. market Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, March 06, 2018, 06:00 am EST – Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic…

Read More